Prescribing information



LEQVIO® is recommended by NICE4


Find out how to start LEQVIO® in primary and secondary care

In clinical trials, LEQVIO® had a safety profile similar to placebo, apart from injection-site reactions2,3

Learn more about the safety data of LEQVIO®


The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.1,2




*After an initial dose, LEQVIO® is administered again at 3 months, followed by every 6 months.2,3
(79.4%). Orion 8 (n=3,274) assessed the long-term efficacy and safety of LEQVIO® in patients who entered an open-label extension after completing either ORION-3, ORION-9, ORION-10 or ORION-11 trials. Patients had a baseline LDL-C of 2.92 mmol/L (± 1.2) and the primary endpoints were the proportion of patients achieving pre-specified LDL-C goals at end of study, and safety. Mean cumulative exposure to LEQVIO® in ORION-8 was 3.7 years with a maximum of 6.8 years.1
National CVDPREVENT data covering the period up to March 2022. Data was received from 96.6% of GP practices, including approximately 18 million patients.5

ASCVD, atherosclerotic cardiovascular disease; GP, general practioner; LDL-C, low-density lipoprotein cholesterol; QOF, Quality and Outcomes Framework.



  1. Wright RS, et al. Oral presentation. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. ESC Congress 2023. Amsterdam, The Netherlands, 25–28 August 2023.
  2. LEQVIO® Great Britain. Summary of Product Characteristics.
  3. LEQVIO® Northern Ireland. Summary of Product Characteristics.
  4. National Institute for Care and Excellence. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. Available at: htt​ps://​w​​inclisiran-for-treating-primary-hypercholesterolaemia-or-mixed-dyslipidaemia-​​ pdf-82611252825541 [Accessed October 2023].
  5. Healthcare Quality Improvement Partnership. [Accessed October 2023].
  6. Raal FJ, et al. N Engl J Med 2020;382:1520–1530.
  7. Ray KK, et al. N Engl J Med 2020;382:1507–1519.
  8. Ray KK, et al. Eur Heart J 2022;43(48):5047–5057.

LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.

Rate this content: 
Average: 4.1 (13 votes)
UK | November 2023 | 301962

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]